Endo Past Earnings Performance

Past criteria checks 2/6

Endo has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 1.8% annually. Revenues have been declining at an average rate of 10.3% per year. Endo's return on equity is 210.4%, and it has net margins of 188.1%.

Key information

0.3%

Earnings growth rate

7.3%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	-10.3%
Return on equity	210.4%
Net Margin	188.1%
Next Earnings Update	11 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Endo makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:NDOI Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	1,790	3,368	543	103
30 Jun 24	1,816	3,573	534	114
31 Mar 24	1,916	-2,599	547	114
31 Dec 23	2,012	-2,448	568	115
30 Sep 23	2,070	-252	598	118
30 Jun 23	2,160	-942	652	118
31 Mar 23	2,182	-2,847	697	119
31 Dec 22	2,319	-2,910	758	121
30 Sep 22	2,552	-3,221	832	129
30 Jun 22	2,783	-2,552	881	123
31 Mar 22	2,928	-681	870	122
31 Dec 21	2,993	-569	841	122
30 Sep 21	2,964	129	767	147
30 Jun 21	2,827	109	687	150
31 Mar 21	2,801	137	688	151
31 Dec 20	2,903	247	671	120
30 Sep 20	2,908	-102	661	125
30 Jun 20	3,002	-75	667	133
31 Mar 20	3,014	-190	648	129
31 Dec 19	2,914	-361	632	131
30 Sep 19	2,936	-418	639	122
30 Jun 19	2,952	-522	635	125
31 Mar 19	2,967	-477	630	181
31 Dec 18	2,947	-962	646	186
30 Sep 18	2,929	-968	640	209
30 Jun 18	2,971	-921	612	209
31 Mar 18	3,132	-1,565	620	168
31 Dec 17	3,469	-1,233	615	172
30 Sep 17	3,942	-4,294	666	170
30 Jun 17	4,039	-4,386	717	175
31 Mar 17	4,084	-3,300	754	185
31 Dec 16	4,010	-3,224	771	183
30 Sep 16	3,842	553	802	181
30 Jun 16	3,704	-59	760	158
31 Mar 16	3,518	-539	721	126
31 Dec 15	3,269	-300	704	102
30 Sep 15	2,858	-725	592	89
30 Jun 15	2,766	128	649	88
31 Mar 15	2,624	260	616	100
31 Dec 14	2,381	58	568	113
30 Sep 14	2,303	-643	609	116
30 Jun 14	2,310	-637	599	132
31 Mar 14	2,429	-650	722	135

Quality Earnings: NDOI has a high level of non-cash earnings.

Growing Profit Margin: NDOI became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NDOI has become profitable over the past 5 years, growing earnings by 0.3% per year.

Accelerating Growth: NDOI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NDOI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42.6%).

Return on Equity

High ROE: Whilst NDOI's Return on Equity (210.42%) is outstanding, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/22 21:04
End of Day Share Price	2025/02/21 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Gary Nachman	BMO Capital Markets Equity Research
Sumant Satchidanand Kulkarni	BofA Global Research